US › Healthcare

BioCryst Pharmaceuticals Inc (BCRX)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$9.02+2.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$156.4M
Revenue YoY
+7.5%
Net profit
$-721.8M
Profit YoY
-2255762.5%
EPS
$0.14
EPS estimate
$0.11
Net margin
-461.5%

EPS came in at 0.14 against a street estimate of 0.11 — a beat of 27.3%.

Key statistics

Market cap
$2.24B
Forward P/E
87.0
P/B
56.59
Book value
$-2.18
EPS (TTM)
$-1.77
52-week high
$11.22
52-week low
$6.00
50-day MA
$9.26
200-day MA
$8.23
Beta
0.55

Analyst view

Analysts rate BioCryst Pharmaceuticals Inc a buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $21.00.

Shareholding

Insiders
1.20%
Institutions
100.31%

Largest institutional holders

FundStake
BlackRock Inc8.91%
Vanguard Group Inc8.76%
RA Capital Management, LLC6.23%
Deerfield Management Co5.92%
State Street Corp4.80%
Vanguard Portfolio Management, LLC4.42%
Vanguard Capital Management, LLC4.38%
TCG Crossover Management, LLC4.34%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioCryst Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.